These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 25884680)

  • 1. Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.
    Matsumoto M; Seike M; Noro R; Soeno C; Sugano T; Takeuchi S; Miyanaga A; Kitamura K; Kubota K; Gemma A
    BMC Cancer; 2015 Apr; 15():241. PubMed ID: 25884680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells.
    Katsha A; Wang L; Arras J; Omar OM; Ecsedy J; Belkhiri A; El-Rifai W
    Clin Cancer Res; 2017 Jul; 23(14):3756-3768. PubMed ID: 28073841
    [No Abstract]   [Full Text] [Related]  

  • 3. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
    Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
    Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
    D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
    Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer.
    Satheesha S; Cookson VJ; Coleman LJ; Ingram N; Madhok B; Hanby AM; Suleman CA; Sabine VS; Macaskill EJ; Bartlett JM; Dixon JM; McElwaine JN; Hughes TA
    Mol Cancer; 2011 Feb; 10():19. PubMed ID: 21320304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
    Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
    Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001.
    Kuo SH; Hsu CH; Chen LT; Lu YS; Lin CH; Yeh PY; Jeng HJ; Gao M; Yeh KH; Cheng AL
    Eur J Cancer; 2011 May; 47(8):1244-57. PubMed ID: 21334199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.
    Huang XB; Yang CM; Han QM; Ye XJ; Lei W; Qian WB
    Acta Pharmacol Sin; 2018 Dec; 39(12):1894-1901. PubMed ID: 30297804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
    Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.
    Ilic N; Utermark T; Widlund HR; Roberts TM
    Proc Natl Acad Sci U S A; 2011 Sep; 108(37):E699-708. PubMed ID: 21876152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
    Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
    Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma proteostasis can be targeted via translation initiation factor eIF4E.
    Zismanov V; Attar-Schneider O; Lishner M; Heffez Aizenfeld R; Tartakover Matalon S; Drucker L
    Int J Oncol; 2015 Feb; 46(2):860-70. PubMed ID: 25422161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosome-mediated miR-7-5p delivery enhances the anticancer effect of Everolimus via blocking MNK/eIF4E axis in non-small cell lung cancer.
    Liu S; Wang W; Ning Y; Zheng H; Zhan Y; Wang H; Yang Y; Luo J; Wen Q; Zang H; Peng J; Ma J; Fan S
    Cell Death Dis; 2022 Feb; 13(2):129. PubMed ID: 35136028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
    Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
    Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
    Hurvitz SA; Kalous O; Conklin D; Desai AJ; Dering J; Anderson L; O'Brien NA; Kolarova T; Finn RS; Linnartz R; Chen D; Slamon DJ
    Breast Cancer Res Treat; 2015 Feb; 149(3):669-80. PubMed ID: 25663547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer.
    Kyou Kwon J; Kim SJ; Hoon Kim J; Mee Lee K; Ho Chang I
    Urol Oncol; 2014 Jan; 32(1):51.e27-35. PubMed ID: 24239466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers.
    Pourdehnad M; Truitt ML; Siddiqi IN; Ducker GS; Shokat KM; Ruggero D
    Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11988-93. PubMed ID: 23803853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies.
    Alain T; Morita M; Fonseca BD; Yanagiya A; Siddiqui N; Bhat M; Zammit D; Marcus V; Metrakos P; Voyer LA; Gandin V; Liu Y; Topisirovic I; Sonenberg N
    Cancer Res; 2012 Dec; 72(24):6468-76. PubMed ID: 23100465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
    Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.